Denali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes Sells 3,339 Shares of Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes sold 3,339 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total value of $69,484.59. Following the completion of the transaction, the director now owns 25,757 shares in the company, valued at approximately $536,003.17. This trade represents a 11.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $21.25 on Thursday. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.33. The stock has a 50-day moving average price of $24.34 and a 200 day moving average price of $24.88. The company has a market capitalization of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the prior year, the firm posted ($0.72) earnings per share. As a group, equities research analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on DNLI. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday. Jefferies Financial Group upped their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. HC Wainwright lowered their price target on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a report on Tuesday. Finally, JPMorgan Chase & Co. reduced their price objective on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.91.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. CWM LLC increased its position in shares of Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after purchasing an additional 654 shares during the last quarter. Quest Partners LLC acquired a new position in Denali Therapeutics in the third quarter worth about $73,000. Assetmark Inc. increased its holdings in Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after buying an additional 580 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after buying an additional 920 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Denali Therapeutics during the 2nd quarter worth approximately $194,000. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.